KIR2DS1 Antibody

說(shuō)明書

中文名稱：

KIR2DS1兔多克隆抗體
貨號(hào)：

CSB-PA623946LA01HU
規(guī)格：

￥440
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品名稱：

Rabbit anti-Homo sapiens (Human) KIR2DS1 Polyclonal antibody
Uniprot No.：

Q14954
基因名：

KIR2DS1
別名：

KIR2DS1 antibody; CD158HKiller cell immunoglobulin-like receptor 2DS1 antibody; CD158 antigen-like family member H antibody; MHC class I NK cell receptor Eb6 ActI antibody; CD antigen CD158h antibody
宿主：

Rabbit
反應(yīng)種屬：

Human
免疫原：

Recombinant Human Killer cell immunoglobulin-like receptor 2DS1 protein (22-245AA)
免疫原種屬：

Homo sapiens (Human)

標(biāo)記方式：

Non-conjugated

本頁(yè)面中的產(chǎn)品，KIR2DS1 Antibody (CSB-PA623946LA01HU)，的標(biāo)記方式是Non-conjugated。對(duì)于KIR2DS1 Antibody，我們還提供其他標(biāo)記。見(jiàn)下表：

標(biāo)記方式	貨號(hào)	產(chǎn)品名稱	應(yīng)用
HRP	CSB-PA623946LB01HU	KIR2DS1 Antibody, HRP conjugated	ELISA
FITC	CSB-PA623946LC01HU	KIR2DS1 Antibody, FITC conjugated
Biotin	CSB-PA623946LD01HU	KIR2DS1 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA
Protocols：

ELISA Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

Receptor on natural killer (NK) cells for some HLA-C alleles such as w6. Does not inhibit the activity of NK cells.
基因功能參考文獻(xiàn)：
1. we demonstrated peptide-dependent binding of the activating NK cell receptor KIR2DS1, providing new insights into the underlying mechanisms involved in KIR2DS1-related disorders. PMID: 28546555
2. Study findings determined the detrimental impact of KIR2DS1, 2DS5, 3DS1, 2DL5 and CxT4 genotype on genetic predisposition to head and neck squamous cell carcinoma in Iranians. PMID: 29408295
3. KIR2DS1 expression by decidual natural killer cells increases their ability to control placental HCMV infection PMID: 27956621
4. A negative association between the KIR2DS1 polymorphism and susceptibility to type 1 diabetes mellitus was found. PMID: 29384924
5. KIR2DS1 gene polymorphism is associated with HIV-1 infection. PMID: 26888639
6. The absence of KIR-2DS1 in the mother and the presence of HLA-C2 ligand in the child were negatively associated with type 1 diabetes in the child. Our results indicate that maternal KIR genes and their interaction with foetal HLA-C2 may contribute to the risk of type 1 diabetes among Han Chinese children PMID: 26991115
7. KIR2DS1-C2C2 is less frequent in type 1 diabetes in Saudi children PMID: 26542066
8. Recurrent Pregnancy Loss in Women with Killer Cell Immunoglobulin-Like Receptor KIR2DS1 is Associated with an Increased HLA-C2 Allelic Frequency PMID: 26589762
9. functional interactions between KIR and HLA modify risks of BCC and SCC and that KIR encoded by the B genes provides selective pressure for altered p53 in BCC tumors. PMID: 26744525
10. The activating KIR gene KIR2DS1 has an important predictive potential for early onset of type 1 autoimmune hepatitis. PMID: 26744892
11. Absence of HLA-C2 for donor KIR2DL1 was associated with higher grade II to IV (HR, 1.4; P = .002) and III to IV acute GVHD (HR, 1.5; P = .01) compared with HLA-C2(+) patients. PMID: 25960307
12. frequency of the maternal KIR2DS1 gene lower in the preeclampsia group than control group PMID: 24911933
13. Data show that KIR2DL5 receptor, KIR2DS1 protein, KIR2DS5 protein and KIR3DS1 receptors were all significantly associated with high viral load. PMID: 25253288
14. the frequencies of HLA-Cw07 were statistically significantly higher in the patient group than those in the control group (P = 0.009). KIR2DS1(+) HLA(-) Cw(Lys) was more common in subjects with SLE PMID: 25581336
15. Moreover, the frequency of activating genotypes in the AS patient group was significantly higher than in the healthy control group (P < 0.05). KIR2DS1 and KIR3DS1 PMID: 25491925
16. Effect of KIR2DS1 was most significant in pregnancies where its ligand, HLA-C2, was paternally but not maternally inherited by a fetus (p = 0.005, odds ratio = 2.65). PMID: 24778445
17. Different expression levels of KIR2DL1 may contribute to the abnormal function of natural killer (NK) and NKT lymphocytes, which lead to the risk of systemic lupus erythematosus (SLE) susceptibility. PMID: 24839813
18. A negative association was found between the activating KIR2DS1 gene and multiple sclerosis. PMID: 24529855
19. Activation of KIR2DS1 positive decidual natural killer cells by HLA-C2 stimulated production of soluble products including GM-CSF. PMID: 24091323
20. Frequencies of the great majority of KIR genes did not differ between patients and controls, except for KIR2DS1, whose frequency was significantly lower in patients than in controls PMID: 23831511
21. many NK cells with anti-HLA-C2 reactivity are present in HLA-C1 homozygous and heterozygous donors with KIR2DS1. PMID: 23554313
22. Activating KIR genes from donors were associated with distinct outcomes of allogeneic HSCT for AML. Donor KIR2DS1 appeared to provide protection against relapse in an HLA-C-dependent manner, and donor KIR3DS1 was associated with reduced mortality. PMID: 22931314
23. Data found that the frequencies of KIR2DS1, 2DS3 and 3DS1 were significantly higher in pulmonary tuberculosis patients than in the control group. PMID: 22653583
24. High KIR2DS1 activation is associated with breast cancer. PMID: 21479698
25. in this cohort, KIR2DS1(+) patients had significantly lower 2-year probabilities of achieving CCyR and OS than KIR2DS1(-) patients. The impact of KIR2DS1 on CCyR was greatest when the ligand for the corresponding inhibitory receptor, KIR2DL1, was absent PMID: 21844874
26. In this study, KIR2DS1+HLA-C2 and KIR3DL1+HLA-B Bw4 Ile80 combinations were associated with the vulnerability to ankylosing spondylitis. PMID: 21797986
27. KIR2DS1 expression may also significantly amplify the size of the alloreactive NK cell subset by switching a subset of "not alloreactive" NK cells into potent alloreactive cells. PMID: 21791599
28. In alloreactive natural killer-cell responses, KIR2DS1 expression represents a remarkable advantage as it allows efficient killing of C2/C2 or C1/C2 myelomonocitic dendritic cells (DCs) and T-cell blasts. PMID: 21355085
29. This study suggested that the presence of functional compounds of activating KIR receptors together with their HLA ligands, allowing the immunomodulatory function of NK cells, may have a protective role against the disease. PMID: 20826009
30. Study showed that the activating KIR2DS1 and KIR2DS3 genes associate with fatal outcome in Ebola virus infection. PMID: 20878400
31. KIR2DS1 has been associated with autoimmunity and hematopoietic stem cell transplantation, these results pave the way to dissect the function of KIR2DS1 in these clinical conditions. PMID: 20093094
32. KIR3DS1 and KIR2DS1 may be necessary to trigger an effective early immune response against HPV-infected targets to establish resistance to recurrent respiratory papillomatosis PMID: 19861144
33. individuals carrying three activating KIR genes 3DS1, 2DS1, and 2DS5 are more frequent in patients with Vogt-Koyanagi-Harada disease than in controls PMID: 19897003
34. KIR2DS1 genes are overrepresented in combination with KIR2DS3, KIR3DS1 and KIR2DS5. PMID: 12559621
35. The frequencies of KIR2DS1 and KIR2DL5 were significantly increased in psoriasis vulgaris cases compared with controls PMID: 15140215
36. Results indicate a role of KIR2DS1 on recognition of HLA-Cw6 in susceptibility to psoriasis. PMID: 15310528
37. An increase in the frequency of the activating KIR2DS1 gene was detected in the psoriatic arthritis (PsA) patients, compared with psoriasis patients negative for PsA and an unaffected American Caucasian control group. PMID: 16112031
38. The presence of KIR2DS1 in the donor (n = 16/25) was not demonstrated to influence outcome following donor-hematopoietic cell transplantation. PMID: 16504727
39. Significantly increased KIR2DS1 is associated with systemic lupus erythematosus and scleroderma PMID: 17445179
40. These results suggest that activating KIR2DS1 gene may not confer susceptibility to PV, and an association of KIR2DS1 gene with the HLA-Cw*0602+ was observed in these patients. PMID: 18643961
41. KIR2DS1 incompatibilities increased risk of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation PMID: 19500138
42. Data show that sHLA-Cw4 or sHLA-Cw3 alleles induced secretion of TGF-beta1 by ligation of stimulatory KIR2DS1 or KIR2DS2 isoforms. PMID: 19830740
顯示更多

收起更多
亞細(xì)胞定位：

Cell membrane; Single-pass type I membrane protein.
蛋白家族：

Immunoglobulin superfamily
組織特異性：

Expressed by NK cells.
數(shù)據(jù)庫(kù)鏈接：

HGNC: 6333

OMIM: 604952

KEGG: hsa:3806

UniGene: Hs.744319

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human